82P Stock Overview Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details
Rewards Risk Analysis No risks detected for 82P from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Pacira BioSciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Pacira BioSciences Historical stock prices Current Share Price US$18.20 52 Week High US$32.20 52 Week Low US$10.70 Beta 0.80 1 Month Change 15.19% 3 Month Change 43.31% 1 Year Change -40.52% 3 Year Change -66.61% 5 Year Change -54.73% Change since IPO 280.83%
Recent News & Updates
Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee Nov 15
Third quarter 2024 earnings released: US$3.11 loss per share (vs US$0.23 profit in 3Q 2023) Nov 07 Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024
Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 30
Pacira BioSciences, Inc. Announces Chief Financial Officer Changes Oct 21
Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 Oct 03 See more updates
Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee Nov 15
Third quarter 2024 earnings released: US$3.11 loss per share (vs US$0.23 profit in 3Q 2023) Nov 07 Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024
Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 30
Pacira BioSciences, Inc. Announces Chief Financial Officer Changes Oct 21
Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 Oct 03 DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences Sep 25
Pacira Biosciences, Inc. Announces Board Changes Sep 11
Investor sentiment deteriorates as stock falls 42% Aug 15
CEO & Director recently bought €91k worth of stock Aug 14
New major risk - Share price stability Aug 12
Second quarter 2024 earnings released: EPS: US$0.41 (vs US$0.56 in 2Q 2023) Jul 31
Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024 Jul 23
Investor sentiment deteriorates as stock falls 23% Jul 05 Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.
Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024 May 01
Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024 Apr 23
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee Mar 14
Independent Director recently sold €3.3m worth of stock Mar 11
Full year 2023 earnings released: EPS: US$0.91 (vs US$0.35 in FY 2022) Mar 01
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024 Mar 01 Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024
Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy Feb 15
High number of new directors Feb 01 Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024
Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications Nov 11
Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023 Nov 04
Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022) Nov 03
Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors Oct 11 Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO
New minor risk - Shareholder dilution Aug 06
Second quarter 2023 earnings released: EPS: US$0.56 (vs US$0.44 in 2Q 2022) Aug 03
Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Chief Financial Officer recently sold €854k worth of stock Jun 12
Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023 May 06
First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 profit in 1Q 2022) May 03
Now 21% undervalued Apr 26
Full year 2022 earnings released: EPS: US$0.35 (vs US$0.95 in FY 2021) Mar 01
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021) Nov 04
Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Insufficient new directors Oct 14
Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy Sep 22
Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older Sep 21
Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty Sep 08
Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28 Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022 Jul 15
Chief Clinical Officer recently sold €52k worth of stock Jul 09
Chairman & CEO recently sold €687k worth of stock Jun 10
Independent Director recently sold €56k worth of stock May 13
First quarter 2022 earnings released: EPS: US$0.15 (vs US$0.24 in 1Q 2021) May 06
Insufficient new directors Apr 27
Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022 Apr 23
Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022 Apr 13
Insufficient new directors Mar 07
Pacira BioSciences, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 17
Third quarter 2021 earnings released: EPS US$0.40 (vs US$3.03 in 3Q 2020) Nov 06
Pacira BioSciences, Inc Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries Sep 23
Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.17 loss in 2Q 2020) Aug 04
Insufficient new directors Aug 04
Pacira Biosciences, Inc. Announces FDA Approval of Enhanced Exparel Manufacturing Process Aug 04
Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Growth-Defensive Index Jun 28
Pacira BioSciences, Inc. Announces Top-Line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block May 27
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021 May 12
Pacira Biosciences, Inc. Announces That Product Sales Continue to Be Negatively Impacted by the Covid-19 Pandemic for the Full Year 2021 May 05
Full year 2020 earnings released: EPS US$3.41 (vs US$0.27 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
Pacira BioSciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
New 90-day high: €63.50 Feb 13
New 90-day high: €57.50 Jan 09
Investor sentiment improved over the past week Jan 07
Pacira BioSciences, Inc. Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain Nov 19
Market bids up stock over the past week Nov 14
New 90-day low: €42.40 Nov 10
Pacira BioSciences, Inc. Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain Sep 19
An undisclosed buyer acquired an unknown stake in Pacira BioSciences, Inc. from Hercules Capital, Inc. (NYSE:HTGC). Sep 11 Pacira BioSciences, Inc. Not to Provide Financial Guidance for the Full Year 2020 Aug 08
Shareholder Returns 82P DE Pharmaceuticals DE Market 7D -1.1% -0.3% -0.3% 1Y -40.5% -17.0% 7.0%
See full shareholder returns
Return vs Market: 82P underperformed the German Market which returned 7% over the past year.
Price Volatility Is 82P's price volatile compared to industry and market? 82P volatility 82P Average Weekly Movement 6.2% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 82P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 82P's weekly volatility (6%) has been stable over the past year.
About the Company Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
Show more Pacira BioSciences, Inc. Fundamentals Summary How do Pacira BioSciences's earnings and revenue compare to its market cap? 82P fundamental statistics Market cap €863.75m Earnings (TTM ) -€87.17m Revenue (TTM ) €667.71m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 82P income statement (TTM ) Revenue US$694.96m Cost of Revenue US$255.38m Gross Profit US$439.58m Other Expenses US$530.31m Earnings -US$90.73m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.97 Gross Margin 63.25% Net Profit Margin -13.06% Debt/Equity Ratio 78.4%
How did 82P perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 20:46 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pacira BioSciences, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Richard Silver Barclays Balaji Prasad Barclays Anita Dushyanth Berenberg
Show 31 more analysts 
